Exploiting interleukin 6 in multicentric Castleman's disease
- PMID: 25042200
- DOI: 10.1016/S1470-2045(14)70333-X
Exploiting interleukin 6 in multicentric Castleman's disease
Comment on
-
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical